Laboratory diagnosis of antiphospholipid syndrome

Southern Medical Journal

Volumn 106, Issue 7, 2013, Pages 439-446

  Reddy, Pramod ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antiphospholipid antibody syndrome; Hypercoagulable state; Lupus anticoagulant; Mixing study

Indexed keywords

ANTICOAGULANT AGENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOCORTIN 5; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PROTHROMBIN TIME; REVIEW; SERODIAGNOSIS; STACLOT LA TEST;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL LABORATORY TECHNIQUES; HUMANS;

EID: 84880288760     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31829b9c03     Document Type: Review

References (42)

1. Gresele P, Migliacci R, Vedovati MC. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 2009;123:444-451.
2. Dlott JS, Roubey RA. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep 2012;14:71-78.
3. García-Carrasco M, Galarza-Maldonado C,Mendoza-Pinto C, et al. Infections and the antiphospholipid syndrome. Clin Rev Allergy Immunol 2009;36: 104-108.
4. Delbos V, Abgueguen P, Chennebault JM, et al. Acute cytomegalovirus infection and venous thrombosis: Role of antiphospholipid antibodies. J Infect 2007;54:e47-e50.
5. Kiser KL, Badowski ME. Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection. Pharmacotherapy 2010;30:1292-1302.
6. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019-1027.
7. Gris JC, Quéré I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nîmes Obstetricians and Haematologists StudyVNOHA. Thromb Haemost 2000;84:228-236.
8. Sugi T, Matsubayashi H, Inomo A, et al. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res 2004;30:326-332.
9. de Groot PG, Urbanus RT. The significance of autoantibodies against A2-glycoprotein I. Blood 2012;120:266-274.
10. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998;95:15542-15546.
11. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: An international multicenter study. J Thromb Haemost 2009;7:1767-1773.
12. Bertolaccini ML. Antibodies to prothrombin. Lupus 2012;21:729-731.
13. Bertolaccini ML, Atsumi T, Koike T, et al. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 2005;93:289-297.
14. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005;3:1231-1238.
15. Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: A 15-year longitudinal study. J Thromb Haemost 2007;5:1158-1164.
16. Binder W, Lewis S, Shums Z. Clinical significance of IgG and IgM autoantibodies that target the complex of phosphatidylserine and prothrombin. Lupus 2010;19:C134 [abstract].
17. Rand JH, Wu XX, Andree HA, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding tophospholipids: A "lupus procoagulant" phenomenon. Blood 1998;92:1652-1660.
18. Tomer A, Bar-Lev S, Fleisher S, et al. Antiphospholipid antibody syndrome: The flow cytometric annexin A5 competition assay as a diagnostic tool. Br J Haematol 2007;139:113-120.
19. Rand JH, Wu XX, Lapinski R. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004;104:2783-2790.
20. de LaatB,Wu XX, vanLummelM, et al. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007;109:1490-1494.
21. Rand JH, Arslan AA, Wu XX, et al. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol 2006; 194:182-188.
22. Sahud M, Zhukov O, Mo K, et al. False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies. Haemophilia 2012;18:777-781.
23. Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost 2012;38:385-389.
24. Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. Semin Thromb Hemost 2012;38: 360-374.
25. Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemost 1995;74:1185-1190.
26. Dembitzer FR, Suarez Y, Aledort LM, et al. Screening coagulation testing using the APTT: Which reagent to choose? Am J Hematol 2010; 85:726.
27. Devreese KM. Evaluation of a new silica clotting time in the diagnosis of lupus anticoagulants. Thromb Res 2007;120:427-438.
28. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993;70:787-793.
29. Devreese KM. Evaluation of a new commercial dilute prothrombin time in the diagnosis of lupus anticoagulants. Thromb Res 2008;123:404-411.
30. Martinuzzo M, Adamczuk Y, Varela ML, et al. The activated seven lupus anticoagulant (ASLA) test has comparable sensitivity to classical assays for screening of lupus anticoagulant. Thromb Haemost 2005;93:1007-1009.
31. Forastiero R. Bleeding in the antiphospholipid syndrome. Hematology 2012;17:S153-S155.
32. Favaloro EJ, Reben R, Mohammed S, et al.Aclinical audit of antiphospholipid antibody testing in tertiary practice: Towards improved relevance in thrombophilia investigations. Intern Med J 2012;42:427-434.
33. Liestøl S, Wisløff F. Effect of subcutaneous administration of dalteparin on lupus anticoagulant assays. Thromb Res 2005;115:509-517.
34. Gosselin RC, King JH, Janatpur KA, et al. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med 2004;128:1142-1145.
35. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: The present and the future. Pathology 2011;43:682-692.
36. Kershaw G, Suresh S, Orellana D, et al. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012;38:375-384.
37. van Os GM, de Laat B, Kamphuisen PW, et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 2011;9:1657-1659.
38. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737-1740.
39. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
40. Jennings I, Kitchen S, Kitchen DP, et al. ISTH/SSC lupus anticoagulant testing guidelines: How far have these been adopted by laboratories? J Thromb Haemost 2011;9:2117-2119.
41. Cervera R, Conti F, Doria A, et al. Does seronegative antiphospholipid syndrome really exist? Autoimmun Rev 2012;11:581-584.
42. Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, et al. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). Ann Rheum Dis 2012;71:242-244.